PMC:7530350 / 663-1498 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":534,"end":539},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe) and patients with mild to moderate COVID-19 (non-severe). The included studies were of moderate to high quality. The mean patients’ age was 60.9 years, ranging from 45.2 to 76.7 years in the severe group and 46.8 years, ranging from 37.9 to 61 years, in the nonsevere group. Fifty-two percent were male in the severe group, as compared to 46% in the non-severe group. An overall random effects meta-analysis showed significantly higher serum levels of IL-6 in the severe group than in the non-severe group with a mean difference of +23.1 pg/mL (95% CI: 12.42–33.79) and the overall effect of 4.24 (P-value \u003c 0.001). Meta-regressions showed that neither age nor sex significantly influenced the mean difference of IL-6 between the groups."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":534,"end":539},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe) and patients with mild to moderate COVID-19 (non-severe). The included studies were of moderate to high quality. The mean patients’ age was 60.9 years, ranging from 45.2 to 76.7 years in the severe group and 46.8 years, ranging from 37.9 to 61 years, in the nonsevere group. Fifty-two percent were male in the severe group, as compared to 46% in the non-severe group. An overall random effects meta-analysis showed significantly higher serum levels of IL-6 in the severe group than in the non-severe group with a mean difference of +23.1 pg/mL (95% CI: 12.42–33.79) and the overall effect of 4.24 (P-value \u003c 0.001). Meta-regressions showed that neither age nor sex significantly influenced the mean difference of IL-6 between the groups."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":80,"end":88},"obj":"Disease"},{"id":"T7","span":{"begin":133,"end":141},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe) and patients with mild to moderate COVID-19 (non-severe). The included studies were of moderate to high quality. The mean patients’ age was 60.9 years, ranging from 45.2 to 76.7 years in the severe group and 46.8 years, ranging from 37.9 to 61 years, in the nonsevere group. Fifty-two percent were male in the severe group, as compared to 46% in the non-severe group. An overall random effects meta-analysis showed significantly higher serum levels of IL-6 in the severe group than in the non-severe group with a mean difference of +23.1 pg/mL (95% CI: 12.42–33.79) and the overall effect of 4.24 (P-value \u003c 0.001). Meta-regressions showed that neither age nor sex significantly influenced the mean difference of IL-6 between the groups."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":396,"end":400},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T8","span":{"begin":396,"end":400},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T9","span":{"begin":609,"end":610},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":636,"end":638},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"}],"text":"Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe) and patients with mild to moderate COVID-19 (non-severe). The included studies were of moderate to high quality. The mean patients’ age was 60.9 years, ranging from 45.2 to 76.7 years in the severe group and 46.8 years, ranging from 37.9 to 61 years, in the nonsevere group. Fifty-two percent were male in the severe group, as compared to 46% in the non-severe group. An overall random effects meta-analysis showed significantly higher serum levels of IL-6 in the severe group than in the non-severe group with a mean difference of +23.1 pg/mL (95% CI: 12.42–33.79) and the overall effect of 4.24 (P-value \u003c 0.001). Meta-regressions showed that neither age nor sex significantly influenced the mean difference of IL-6 between the groups."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7","span":{"begin":32,"end":34},"obj":"Chemical"},{"id":"T9","span":{"begin":296,"end":301},"obj":"Chemical"},{"id":"T10","span":{"begin":366,"end":371},"obj":"Chemical"},{"id":"T11","span":{"begin":396,"end":400},"obj":"Chemical"},{"id":"T12","span":{"begin":415,"end":420},"obj":"Chemical"},{"id":"T13","span":{"begin":459,"end":464},"obj":"Chemical"},{"id":"T14","span":{"begin":550,"end":552},"obj":"Chemical"},{"id":"T16","span":{"begin":569,"end":574},"obj":"Chemical"},{"id":"T17","span":{"begin":598,"end":603},"obj":"Chemical"},{"id":"T18","span":{"begin":811,"end":813},"obj":"Chemical"}],"attributes":[{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A8","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A15","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A19","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe) and patients with mild to moderate COVID-19 (non-severe). The included studies were of moderate to high quality. The mean patients’ age was 60.9 years, ranging from 45.2 to 76.7 years in the severe group and 46.8 years, ranging from 37.9 to 61 years, in the nonsevere group. Fifty-two percent were male in the severe group, as compared to 46% in the non-severe group. An overall random effects meta-analysis showed significantly higher serum levels of IL-6 in the severe group than in the non-severe group with a mean difference of +23.1 pg/mL (95% CI: 12.42–33.79) and the overall effect of 4.24 (P-value \u003c 0.001). Meta-regressions showed that neither age nor sex significantly influenced the mean difference of IL-6 between the groups."}

{"project":"LitCovid-PubTator","denotations":[{"id":"30","span":{"begin":32,"end":36},"obj":"Gene"},{"id":"31","span":{"begin":550,"end":554},"obj":"Gene"},{"id":"32","span":{"begin":811,"end":815},"obj":"Gene"},{"id":"33","span":{"begin":47,"end":55},"obj":"Species"},{"id":"34","span":{"begin":102,"end":110},"obj":"Species"},{"id":"35","span":{"begin":220,"end":228},"obj":"Species"},{"id":"36","span":{"begin":80,"end":88},"obj":"Disease"},{"id":"37","span":{"begin":133,"end":141},"obj":"Disease"}],"attributes":[{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Gene:3569"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"Gene:3569"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"Gene:3569"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"Tax:9606"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Tax:9606"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"Tax:9606"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"MESH:C000657245"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe) and patients with mild to moderate COVID-19 (non-severe). The included studies were of moderate to high quality. The mean patients’ age was 60.9 years, ranging from 45.2 to 76.7 years in the severe group and 46.8 years, ranging from 37.9 to 61 years, in the nonsevere group. Fifty-two percent were male in the severe group, as compared to 46% in the non-severe group. An overall random effects meta-analysis showed significantly higher serum levels of IL-6 in the severe group than in the non-severe group with a mean difference of +23.1 pg/mL (95% CI: 12.42–33.79) and the overall effect of 4.24 (P-value \u003c 0.001). Meta-regressions showed that neither age nor sex significantly influenced the mean difference of IL-6 between the groups."}

{"project":"LitCovid-sentences","denotations":[{"id":"T10","span":{"begin":0,"end":155},"obj":"Sentence"},{"id":"T11","span":{"begin":156,"end":210},"obj":"Sentence"},{"id":"T12","span":{"begin":211,"end":372},"obj":"Sentence"},{"id":"T13","span":{"begin":373,"end":465},"obj":"Sentence"},{"id":"T14","span":{"begin":466,"end":650},"obj":"Sentence"},{"id":"T15","span":{"begin":651,"end":713},"obj":"Sentence"},{"id":"T16","span":{"begin":714,"end":835},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe) and patients with mild to moderate COVID-19 (non-severe). The included studies were of moderate to high quality. The mean patients’ age was 60.9 years, ranging from 45.2 to 76.7 years in the severe group and 46.8 years, ranging from 37.9 to 61 years, in the nonsevere group. Fifty-two percent were male in the severe group, as compared to 46% in the non-severe group. An overall random effects meta-analysis showed significantly higher serum levels of IL-6 in the severe group than in the non-severe group with a mean difference of +23.1 pg/mL (95% CI: 12.42–33.79) and the overall effect of 4.24 (P-value \u003c 0.001). Meta-regressions showed that neither age nor sex significantly influenced the mean difference of IL-6 between the groups."}